Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges

Elizabethkingia meningoseptica is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed ho...

Full description

Saved in:
Bibliographic Details
Main Authors: Fabrizio Tropea, David Fraulino, Jeffrey Aeschlimann, P. Rocco LaSala, Sonia Magano
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:IDCases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250925001040
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850225623005396992
author Fabrizio Tropea
David Fraulino
Jeffrey Aeschlimann
P. Rocco LaSala
Sonia Magano
author_facet Fabrizio Tropea
David Fraulino
Jeffrey Aeschlimann
P. Rocco LaSala
Sonia Magano
author_sort Fabrizio Tropea
collection DOAJ
description Elizabethkingia meningoseptica is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed hosts with an immunocompromised status and/or a prolonged exposure to healthcare settings. Herein, we report a case of a 78-year-old male with newly diagnosed myelodysplastic syndrome initially admitted to the hospital with pneumonia and then re-admitted after discharge with septic shock and evidence of E. meningoseptica bacteremia isolated from blood cultures. Treatment with piperacillin-tazobactam was initiated and later escalated to dual-therapy with the addition of levofloxacin. After hemodynamic stability was achieved, the patient was discharged on oral levofloxacin to complete a 21-day course of therapy. E. meningoseptica displays a unique multi-drug resistant profile that often makes initial antimicrobial selection challenging. This case illustrates the importance of early detection and use of in vitro susceptibility testing to guide therapeutic decision-making in E. meningoseptica infections; a pathogen known to have both high morbidity and mortality particularly in the immunocompromised.
format Article
id doaj-art-a4ed1570f1ca4955b61879ee1220a42a
institution OA Journals
issn 2214-2509
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series IDCases
spelling doaj-art-a4ed1570f1ca4955b61879ee1220a42a2025-08-20T02:05:17ZengElsevierIDCases2214-25092025-01-0140e0224810.1016/j.idcr.2025.e02248Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challengesFabrizio Tropea0David Fraulino1Jeffrey Aeschlimann2P. Rocco LaSala3Sonia Magano4University of Connecticut Health Center, Farmington, CT, United States; Corresponding author.University of Connecticut Health Center, Farmington, CT, United StatesUniversity of Connecticut Health Center, Farmington, CT, United States; University of Connecticut School of Pharmacy, Storrs, CT, United StatesUniversity of Connecticut Health Center, Farmington, CT, United StatesUniversity of Connecticut College of Agriculture, Health, and Natural Resources, Storrs, CT, United StatesElizabethkingia meningoseptica is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed hosts with an immunocompromised status and/or a prolonged exposure to healthcare settings. Herein, we report a case of a 78-year-old male with newly diagnosed myelodysplastic syndrome initially admitted to the hospital with pneumonia and then re-admitted after discharge with septic shock and evidence of E. meningoseptica bacteremia isolated from blood cultures. Treatment with piperacillin-tazobactam was initiated and later escalated to dual-therapy with the addition of levofloxacin. After hemodynamic stability was achieved, the patient was discharged on oral levofloxacin to complete a 21-day course of therapy. E. meningoseptica displays a unique multi-drug resistant profile that often makes initial antimicrobial selection challenging. This case illustrates the importance of early detection and use of in vitro susceptibility testing to guide therapeutic decision-making in E. meningoseptica infections; a pathogen known to have both high morbidity and mortality particularly in the immunocompromised.http://www.sciencedirect.com/science/article/pii/S2214250925001040Elizabethkingia meningosepticaBacteremia: Immunocompromise: Nosocomial pathogen
spellingShingle Fabrizio Tropea
David Fraulino
Jeffrey Aeschlimann
P. Rocco LaSala
Sonia Magano
Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
IDCases
Elizabethkingia meningoseptica
Bacteremia: Immunocompromise: Nosocomial pathogen
title Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
title_full Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
title_fullStr Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
title_full_unstemmed Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
title_short Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges
title_sort elizabethkingia meningoseptica case report on an emerging pathogen and its associated treatment challenges
topic Elizabethkingia meningoseptica
Bacteremia: Immunocompromise: Nosocomial pathogen
url http://www.sciencedirect.com/science/article/pii/S2214250925001040
work_keys_str_mv AT fabriziotropea elizabethkingiameningosepticacasereportonanemergingpathogenanditsassociatedtreatmentchallenges
AT davidfraulino elizabethkingiameningosepticacasereportonanemergingpathogenanditsassociatedtreatmentchallenges
AT jeffreyaeschlimann elizabethkingiameningosepticacasereportonanemergingpathogenanditsassociatedtreatmentchallenges
AT proccolasala elizabethkingiameningosepticacasereportonanemergingpathogenanditsassociatedtreatmentchallenges
AT soniamagano elizabethkingiameningosepticacasereportonanemergingpathogenanditsassociatedtreatmentchallenges